NCCN 癌症治疗指南:卵巢癌2023(英).pdf,NCCN GUIDELINES FOR PATIENTS® 2023 Ovarian Cancer ® NATIONAL COMPREHENSIVE CANCER NETWORK Available online at Presented with support from FOUNDATION NCCN.org/patientguidelines Guiding Treatment. Changing Live
1. NCCN guidelines for ovarian cancer 2020 Version1 2.Perren, Timothy J., et al. "A phase 3 trial ofbevacizumab in ovarian cancer."NewEngland Journal of Medicine365.26 (2011): 2484-2496. 3.Oza, Amit M., et al. "Standard chemo...
NCCN treatment guidelines for ovarian cancer: A population-based validation study of structural and process quality measures. Presented at: Society of Gynecologic Oncology Annual Meeting on Women's Cancer; Los Angeles, CA; March 11, 2013. Gynecol Oncol. 2013;130(1);e18. Available at: http://...
high-risk breast cancer (see eligibility criteria listed on BINV-K). In patients eligible for both adjuvant olaparib and abemaciclib, the optimal choice of therapy and sequencing is not known. (Also for BINV-8)
2021 Ovarian Cancer Presented with support from: Available online at NCCN.org/patients Ü Ovarian Cancer Its easy to get lost in the cancer world Let NCCN Guidelines for Patients® be your guide 9 Step-by-step guides to the cancer care options likely to have the best results 9 Base...
combination with endocrine therapy can be considered in patients with HR+/HER2-negative, high-risk breast cancer (see eligibility criteria listed on BINV-K). In patients eligible for both adjuvant olaparib and abemaciclib, the optimal choice of therapy and sequencing is not known. (Also for BIN...
2022.v1 NCCN临床实践指南:卵巢癌.pdf,® NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer Version 1.2022 — January 18, 2022 NCCN.org ® NCCN Guidelines for P
NCCN 2012 ovarian cancer 翻译版
NCCN肿瘤学临床实践指南 NCCN指南包括输卵管癌和原发性腹膜癌2021.v22021年8月17日NCCN.orgNCCN患者指南 ,网址:patients继续本指南由邱立新医生团队翻译仅供个人学习使用,严禁用于商业,请于下载后24小时删
NCCN 指南索引 NCCNGuidelinesVersion2.2021 目录 卵巢癌 讨论 NCCN卵巢癌指南版本1.2021从版本2.2020更新为: OV-C(10/11) • 增加的参考文献: ► Ray-CoquardI,PautierP,PignataS,etal.Olaparibplusbevacizumabasfirst-linemaintenanceinovariancancer.NEnglJMed2019;381:2416- 2428. ► Gonzalez-MartinA,PothuriB...